Free Trial
NASDAQ:BCAX

Bicara Therapeutics Q4 2024 Earnings Report

Bicara Therapeutics logo
$9.27 -6.39 (-40.80%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$9.20 -0.07 (-0.76%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Bicara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bicara Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Bicara Therapeutics' Q2 2025 earnings is scheduled for Thursday, June 26, 2025

Bicara Therapeutics Earnings Headlines

Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

View Bicara Therapeutics Profile

More Earnings Resources from MarketBeat